ArticleFrontiers in oncology2025
Identification of exosome miRNAs regulated by SPHK2 in human glioma cells.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioma is the most common primary brain tumor, and the WHO 4 glioma, glioblastoma (GB), is a malignant tumor with high invasiveness and mortality. Tumor-associated macrophages (TAMs), as the main immune cells in glioma, play an important role in the growth, invasiveness, immune escape, and drug resistance. The M2 phenotype of macrophages, but not the M1 phenotype, promotes glioma development. Recent studies have shown that sphingosine kinase 2 (SPHK2) is positively associated with TAM infiltration and glioma proliferation. SPHK2-deficient tumors showed impaired growth and failed to polarize macrophages toward an M2 phenotype. Objective: Our aim was to reveal whether SPHK2 affects exosome microRNA (miRNA) release from glioma cells and which miRNAs regulated by SPHK2 could mediate the polarization of macrophages around glioma cells. Methods: SPHK2 knockdown of the human glioma cell line U373 was performed using short hairpin RNA (shRNA) lentiviruses. Exosome miRNAs were isolated and evaluated using RNA sequencing (RNA-seq). Gene Ontology (GO) analysis was carried out to determine the function of exosome miRNAs targeting genes. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was used to view the pathways of these genes. Results: We successfully isolated exosomes from the U373-HK and U373-SH glioma cell lines. We found 12 exosome miRNAs differentially expressed between U373-HK and U373-SH cells. The heatmap showed two upregulated and 10 downregulated miRNAs in glioma cells with SPHK2 knockdown. There were 12 miRNAs targeting genes assigned to 118 GO terms, including 53 biological processes, 30 cellular components, and 35 molecular function terms. KEGG mapping further clustered several signaling pathways, such as "Wnt signaling," "p53 signaling," "proteoglycans in cancer," and "cell cycle." "Wnt signaling" was identified as the most significantly enriched pathway in the KEGG analysis. A total of 17 genes were enriched in this pathway. Conclusions: The present study elucidates that SPHK2 promoted the release of 10 exosome miRNAs, but inhibited the release of two miRNAs. The KEGG data indicated that these miRNAs targeted several important genes of Wnt signaling. This study provides not only a genomic resource for further studies but also novel insights into uncovering the molecular mechanism of SPHK2 regulating M2 TAM polarization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.